| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8223791 | International Journal of Radiation Oncology*Biology*Physics | 2012 | 8 Pages |
Abstract
In terms of pharmaceutical sponsorship, Genentech was the most active sponsor of radiation therapy combinations (22%), followed by AstraZeneca (14%). Most radiation therapy combination trials do not appear to be initiated until after drug approval. In phase III studies, the most common (58%) primary endpoint was overall survival. Collectively, this analysis suggests that such trials are not given priority by pharmaceutical companies. The potential reasons for this and some challenges and possible solutions are discussed.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Ozlem U. MD, PhD, Sally J. PhD, Chris BSc, Andrew BSc, Amanda E. PhD, Stephen R. PhD,